Miglustat

Miglustat (N-Butyldeoxynojirimycin) is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease[1].

Product Specifications

CAS Number

[72599-27-0]

Product Name Alternative

N-Butyldeoxynojirimycin; NB-DNJ; OGT 918

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Glucosylceramide Synthase (GCS)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/miglustat.html

Purity

99.86

Solubility

H2O : 250 mg/mL (ultrasonic)

Smiles

O[C@H]1[C@H](O)[C@@H](CO)N(CCCC)C[C@@H]1O

Molecular Formula

C10H21NO4

Molecular Weight

219.28

Precautions

H315, H319, H335

References & Citations

[1]Maria Cristina Dechecchi, et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. J Cyst Fibros. 2008 Nov;7 (6) :555-65. |[2]G D'Arcangelo, et al. Miglustat Reverts the Impairment of Synaptic Plasticity in a Mouse Model of NPC Disease. Neural Plast. 2016:2016:3830424.